Navigation Links
Lotus Clinical Research Executive to Present on Opioid Sparing Endpoints at 11th Annual Pain & Migraine Therapeutics Summit
Date:8/22/2017

One of the biggest opportunities to reduce the dependency on opioids in pain management is the practice of opioid-dose sparing. Opioid-dose sparing refers to the reduction of opioid dosage by combining with a non-opioid. This practice has shown promising results, including with non-steroidal anti-inflammatory drugs (NSAIDs).

The potential for new therapies to replace opioids and/or reduce dosages, however, is limited by the success of clinical trials and the utilization of effective endpoints for judging efficacy. Dr. Neil Singla, Chief Scientific Officer of Lotus Clinical Research will discuss these endpoints and criteria for submission of opioid-sparing labels to the FDA at the 11th Annual Pain and Migraine Therapeutics Summit, taking place in San Diego, CA on September 27-28, 2017. For more information, please visit: http://paintherapeuticsummit.com/brochure.

Dr. Singla will outline the regulatory criteria required when seeking an opioid-sparing claim on drug labels. He will provide examples of recently approved drugs for which opioid-sparing claims were sought, both successfully and unsuccessfully. He will also review labels, protocol designs and endpoints, and resulting publications for these drugs. Lastly, he will elaborate on the types of opioid-sparing labels the FDA awards.

Lotus Clinical Research, a specialty analgesic CRO and research site, has performed more than 100 analgesic clinical trials, as well as guided several analgesic agents through FDA approval. Dr. Singla’s expertise will provide attendees of the conference will an informative overview of maneuvering these labels. For more information on the services provided by Lotus Clinical Research, please visit: http://www.lotuscr.com/.

This annual conference provides a discussion platform for key industry and academic research leaders to network and deliberate many themes, including cutting-edge drug discovery science, preclinical development trends, analysis of novel clinical-stage pain therapies and newly marketed products. We will highlight the field’s most important developments in recent years, including: Nav 1.7 sodium channel blocker research, safer opioid analgesics, anti-CGRP receptor monoclonal antibodies, abuse-deterrent opioid development and more.

Please visit http://www.paintherapeuticsummit.com/agenda for the full agenda, which also includes numerous presentations covering clinical trial design and endpoints, regulatory and commercial issues, tools and technologies supporting pain drug discovery, and new scientific discoveries.

For more information, contact:
John Waslif: Managing Director
Arrowhead Publishers
866-945-0263 ext 700
john.waslif(at)arrowheadpublishers(dot)com

Rachel Donlon: Marketing Associate
Arrowhead Publishers
866-945-0263 ext 701
rachel.donlon(at)arrowheadpublishers(dot)com

Read the full story at http://www.prweb.com/releases/2017/08/prweb14618097.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Lotus Bio-Technology Reveals Financial Position of Strategic Partner, as Relationship Strengthens with the Creation of New CBD Product Line
2. Successful FDA Inspection at AXIS Clinicals USA
3. The Conference Forum confirms agenda for the 4th annual Mobile in Clinical Trials event on September 6, 2017
4. DrugDev and SCRS Present Educational Webinar on How to Develop an Efficient and Compliant Clinical Trial Start-Up Process
5. Myoderm Adds Clinical Trial Supply Veteran to Business Development Team -- New UK Warehouse Operational and Increasing Drug Supply Volume
6. 7th Annual DPharm: Disruptive Innovations to Advance Clinical Trials Conference Confirms Program Line-up for September 7-8, 2017
7. Former VP of Clinical Pharmacology at Nektar Therapeutics, Michael A. Eldon, PhD, FCP, Joins NDA Partners as Expert Consultant
8. Litmus Health Announces Advisory Board as Real-Life Data Gain Traction in Clinical Trials
9. TrialKit™ Allows Researchers to Easily Employ Core Motion and HealthKit™ on iPhone® and Apple Watch® in Clinical Trials
10. Microscan To Demonstrate Advancements in Barcode and Machine Vision Technology at AACC Clinical Lab Expo 2017
11. BioTech Holdings Announces First Clinical Use of Microbiome Optimized Autologous Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... the three Winners and six Finalists of the 2017 Blavatnik Regional Awards for ... Blavatnik Family Foundation and administered by the New York Academy of Sciences to ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... States multicenter, prospective clinical study that demonstrates the accuracy of the FebriDx® ... identifying clinically significant acute bacterial and viral respiratory tract infections by testing ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... partners with the pharmaceutical and biotechnology industries to improve patient outcomes and quality ... Several trends in analytical testing are being attributed to new regulatory requirements for ...
(Date:10/11/2017)... Charlotte, N.C. (PRWEB) , ... October 11, 2017 ... ... ARCS® Foundation President Andi Purple announced Dr. Suneel I. Sheikh, the ... Laboratories ( ASTER Labs ), Inc. has been selected for membership in ...
Breaking Biology Technology:
(Date:6/30/2017)... , June 30, 2017 Today, ... developer and supplier of face and eye tracking ... Featured Product provider program. "Artificial ... innovative way to monitor a driver,s attentiveness levels ... from being able to detect fatigue and prevent ...
(Date:5/16/2017)...  Veratad Technologies, LLC ( www.veratad.com ), an innovative ... verification solutions, announced today they will participate as a ... thru May 17, 2017, in Washington D.C.,s ... Identity impacts the lives of billions ... evolving digital world, defining identity is critical to nearly ...
(Date:4/19/2017)... ALBANY, New York , April 19, 2017 /PRNewswire/ ... highly competitive, as its vendor landscape is marked by ... in the market is however held by five major ... and Safran. Together these companies accounted for nearly 61% ... majority of the leading companies in the global military ...
Breaking Biology News(10 mins):